Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of "Buy" from Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have received an average recommendation of "Buy" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $28.83.

Several research firms have recently weighed in on IMNM. Stephens initiated coverage on shares of Immunome in a report on Friday, November 8th. They set an "overweight" rating and a $30.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and set a $33.00 price target on shares of Immunome in a report on Friday, October 25th. Finally, Piper Sandler reduced their price objective on Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th.

Immunome Stock Performance

Shares of NASDAQ:IMNM traded down $0.11 on Friday, hitting $10.97. The stock had a trading volume of 1,453,565 shares, compared to its average volume of 782,940. The company has a market capitalization of $684.71 million, a price-to-earnings ratio of -1.35 and a beta of 1.83. The firm's 50 day moving average price is $12.14 and its 200-day moving average price is $13.35. Immunome has a twelve month low of $8.15 and a twelve month high of $30.96.

Insider Transactions at Immunome

In other Immunome news, CEO Clay B. Siegall bought 66,057 shares of the stock in a transaction on Thursday, November 21st. The stock was purchased at an average price of $9.54 per share, with a total value of $630,183.78. Following the acquisition, the chief executive officer now owns 485,693 shares of the company's stock, valued at approximately $4,633,511.22. The trade was a 15.74 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CTO Philip Tsai bought 21,000 shares of the company's stock in a transaction on Thursday, November 21st. The shares were acquired at an average price of $9.43 per share, with a total value of $198,030.00. Following the transaction, the chief technology officer now directly owns 21,000 shares in the company, valued at approximately $198,030. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 102,862 shares of company stock worth $978,045 over the last 90 days. 8.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Immunome

A number of institutional investors have recently made changes to their positions in the stock. Quest Partners LLC acquired a new stake in Immunome in the second quarter worth $81,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Immunome during the 2nd quarter worth $97,000. Arizona State Retirement System lifted its holdings in Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company's stock worth $131,000 after acquiring an additional 918 shares in the last quarter. Intech Investment Management LLC acquired a new position in Immunome in the third quarter valued at about $219,000. Finally, AQR Capital Management LLC increased its holdings in shares of Immunome by 34.6% in the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock worth $194,000 after acquiring an additional 4,129 shares in the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.